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BY-NC-ND license (http://creativecomAbstract Background/purpose: Activation of cell surface CD30 by immobilized anti-CD30
monoclonal antibodies (mAb) induces strong apoptosis in human eosinophils. This anti-CD30
mAb-induced eosinophil apoptosis is inhibited by the addition of inhibitors of p38, ERK1/2
mitogen-activated protein kinases, and phosphatidylinositol 3-kinase. However, there is little
data investigating the role of Bcl-2 and caspases in eosinophil apoptosis induced by anti-CD30
mAb. We sought to determine whether anti-CD30 mAb induces human eosinophil apoptosis via
Bcl-2 and caspase pathways.
Methods: Peripheral blood was drawn from 37 healthy volunteers. The CD30 expression on eo-
sinophils was measured at various time points. Eosinophils were then cultured in plates pre-
coated with anti-CD30 mAb (clone Ber-H8), isotype control immunoglobulin G1, interleukin
(IL)-5, or dexamethasone. Western blot analysis was performed to determine the expression
of Bcl-2, procaspase-8, -9, and -3, and caspase-8, -9, and -3 after cross-linking of CD30. Human
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146 H.J. Lee et al.presence or absence of caspase-9 or -3 inhibitors. Eosinophil apoptosis was assessed using flow
cytometry.
Results: The addition of anti-CD30 mAb significantly increased eosinophil apoptosis compared
with controls. In western blot analysis, the addition of anti-CD30 mAb significantly decreased
the expression of Bcl-2 and procaspase-9 and -3 and increased the expression of caspase-9 and
-3. The addition of caspase-9 or -3 inhibitors decreased anti-CD30 mAb-induced human eosin-
ophil apoptosis. Procaspase-8 or caspase-8 expression was not changed in response to various
stimuli.
Conclusion: Anti-CD30 mAb-induced human eosinophil apoptosis is likely to be mediated
through Bcl-2 and caspase-9 and -3.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Eosinophils are resident in various organs such as the res-
piratory tract, the gastrointestinal tract, mammary glands,
and bone marrow. They play an important role in these
organs and in maintaining immune homeostasis of these
organs.1 In T-helper 2 (Th2)-type immune response, eosin-
ophils are recruited into inflammation sites, where they
produce various kinds of cytokines and chemokines and
release toxic granule proteins in response to diverse phys-
iological and artificial stimuli.1 These molecules may
regulate inflammatory immune responses, cause tissue
damage, and promote tissue repair.2 Eosinophils can also
present antigens to naı¨ve and memory T cells and trigger
and/or intensify antigen-specific immune responses.1
Given that eosinophils play essential roles in immune
responses, such as allergic diseases, as both effector and
modulatory cells, many studies have been conducted to
reduce allergic inflammation by selectively inducing
apoptosis of eosinophils.3e7 We have previously shown that
eosinophil survival and apoptosis are regulated by CD98 and
FcgRII.9 The focus of the previous studies was directed
toward the receptors found on the surface of human eo-
sinophils in an attempt to induce eosinophil apoptosis by
cross-linking of the surface molecules.3e7,10,11 Among
them, CD30, a member of the tumor necrosis factor re-
ceptor (TNFR) family, has been found to exist on the
eosinophil surface.3,4,7,12 Although there have been a few
studies demonstrating that cross-linking of CD30 on the
surface of human eosinophil can induce apoptosis through
an intracellular signaling pathway, limited studies have
been carried out to determine the mechanism underlying
the eosinophil apoptosis after cross-linking of CD30 mole-
cules on the surface of eosinophils.3,4,7,12
Neutrophils, mast cells, T cells, and dendritic cells are
important effector cells in allergic diseases. Many proteins
are known to play a role in regulating human cell apoptosis.
Studies have shown that Bcl-213e17 and caspases18e21 play a
crucial role in apoptosis in various types of human he-
matopoietic cells. However, there are few studies in the
literature clarifying the possible role of Bcl-2 and caspases
in human eosinophil apoptosis after cross-linking of CD30.
In the present in vitro study, we sought to determine
whether Bcl-2 and caspase-9 and -3 are involved in the
signal transduction pathways in human eosinophil apoptosis
through cross-linking of CD30.Methods
Human eosinophil preparation
Eosinophils were purified from the peripheral blood of
healthy Individuals (nZ 37) using Percoll-sodium diatrizoate
density gradient (Amershan Pharmacia Biotech, Uppsala,
Sweden) sedimentation and negative selection with anti-
CD16 antibody-coated immunomagnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany) using the FACS Flow
Cytometry (Becton Dickinson Co., Mountain View, CA, USA),
as previously described.22 Briefly, a total of 90 mL of pe-
ripheral blood was obtained from each healthy donor. The
mean number of eosinophils isolated from 90 mL was
11.6  2.3  106 cells. Eosinophils were washed with ice-
cold Phosphate-buffered saline (PBS) before lysing them in
Radio immune precipitation assay (RIPA) buffer (Sigma-
eAldrich, St. Louis, MO, USA) and a cocktail of protease
inhibitors (SigmaeAldrich) at 4C. Protein was extracted by
adding 300 mL of RIPA buffer to 1.2  107 cells. The con-
centrations of total protein varied from 0.82 mg/mL to
2.23 mg/mL. Samples of 30 mg of protein in loading buffer
were transferred from polyacrylamide gels onto a nitrocel-
lulose membrane. Both the purity and viability of the eo-
sinophils were confirmed to exceed 98% based on light
microscopic examination of cytocentrifuged preparations
using Randolph stain and trypan blue dye (SigmaeAldrich)
exclusion, respectively. Written informed consent was ob-
tained from all donors, and the study was approved by the
institutional review board of Uijeongbu St. Mary’s Hospital.
All culture experiments were performed in triplicate.Human eosinophil culture
Purified eosinophils were suspended at a cell density of
1  106/mL in RPMI 1640 media (Atlanta Biologicals, Nor-
cross, GA, USA) supplemented with 1% or 10% Fetal bovine
serum (FBS) (Atlanta Biologicals) and 100 mg/mL strepto-
mycin. CD30 agonistic monoclonal antibodies (mAb), Ber-H8
(BD Pharmingen, San Diego, CA, USA), and control immu-
noglobulin G1 (IgG1; Santa Biotechnology, Santa Cruz, CA,
USA) were used to investigate the effect of CD30 activation
on eosinophil apoptosis. Ber-H8 and IgG1 were suspended in
PBS at a concentration of 20 mg/mL, and 500 mL/well were
transferred to flat bottom 24-well plates (Costar,
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immobilized with the mAb at 4C for 24 hours, the wells
were washed three times with PBS containing 1% Bovine
serum albumin (BSA) and blocked with 1 mL of 1% BSA at 4C
overnight, and then equal numbers of cells were supple-
mented. Each experimental group was incubated in the
RPMI 1640 supplemented with 10% heat inactivated FBS at
different wells in a 37C humidified atmosphere with 5%
CO2 for 0 hours, 4 hours, 24 hours, 66 hours, or 90 hours.
The groups were classified into cells cultured with media
only, 10 ng/mL interleukin (IL)-5, 10mM/mL dexamethasone
(Sigma Chemical Co., St. Louis, MO, USA), 20 mg/mL Ber-H8,
20 mg/mL IgG1, 20 mg/mL Ber-H8 þ 10 ng/mL IL-5, and
20 mg/mL IgG1 þ 10 ng/mL IL-5. Additionally, some purified
eosinophils were also cultured in the presence of caspase-9
inhibitors (Z-LEHD-FMK; BD Pharmingen, San Diego, CA,
USA) or caspase-3 inhibitors (Z-DEVD-FMK; BD Pharmingen)
for 24 hours and 48 hours and the cells were collected and
apoptosis was measured by flow cytometry.
Expression of CD30 on the surface of human
eosinophils
The expression of CD30 on eosinophils was examined using
indirect immunofluorescence and flow cytometry, as previ-
ously described.6 Freshly isolated eosinophils were labeled
(30 minutes, 4C) in PBS containing 1% BSA (PBS-BSA; Sigma-
Aldrich) and 4 mg/mL human IgG (Sigma-Aldrich) with a
saturating concentration of anti-CD30 mAb or an equivalent
concentration of irrelevant isotype-matched control mAb.
Cells were washed and then incubated (30 minutes, 4C in
PBS-BSA) with appropriate dilutions of flourescein
isothiocyanate (FITC)-conjugated F(ab0)2 goat anti-mouse
IgG Ab (BD sciences, Mountain View, CA, USA). After fixa-
tion in 1% paraformaldehyde in PBS, fluorescence analysis
was conducted in the FACS Flow Cytometry. Fluorescence
intensity was determined on 20,000 cells from each sample
using logarithmic amplification, which was converted to the
linear equivalent using Lysis II software (FACScan; Becton
Dickinson Co., Mountain View, CA, USA).
Assessment of human eosinophil apoptosis
The Annexin V-FITC/propidium iodide (PI) Apoptosis Detec-
tion Kit (BD Pharmingen) was used according to the manu-
facturer’s instructions.23 Briefly, eosinophils were harvested
at various time points by gentle pipetting and washed once
with PBS. The harvested eosinophils were then suspended in
a Ca2þ-containing buffer and reacted with FITC-conjugated
Annexin V for 15 minutes at room temperature. One min-
ute before FACS flow cytometry analysis, the eosinophils
were also stained with 10 mg/mL PI. The FITC-stained cells
(Annexin V-positive) and PI-stained cells were assessed using
FACS flow cytometry, as previously described.4
Assessment of Bcl-2, procaspase-8, -9, and -3, and
caspase-8, -9, and -3 expressions in human
eosinophils by western blotting
Eosinophils were collected at 24 hours and protein was
extracted using RIPA Lysis and Extraction Buffer (SigmaAldrich, St. Louis, MO, USA). After centrifugation at 4C,
14000 g for 20 minutes, protein concentration was
measured using the Bradford method and diluted with 5X
Sodium dodecyl sulfate (SDS) sample buffer, and then
boiled at 100C for 5 minutes. Protein concentrate of 1 mg/
mL was inoculated to 12.5% polyacrylamide gel, transferred
to a polyvinylidene fluoride membrane, and separated for 1
hour by 100 mV. The membrane was fixed at room tem-
perature for 1 hour in the solution mixed with Tween-20
Tris-buffered saline dissolved in nonfat dry milk. The pri-
mary antibody (Bcl-2, procaspase-8, -9, and -3, and
caspase-8, -9, and -3) was combined to the membrane and
was reacted at 4C overnight. The membrane was washed
with Trips-buffered saline (TBS)/Tween-20 four times
strongly at room temperature and reacted with secondary
antibody at room temperature for 2 hours. We assessed Bcl-
2, procaspase-8, -9, and -3, and caspase-8, -9, and -3 pro-
teins using western blotting luminal reagent kit (Rochester,
NY, USA) and exposed them to Kodak BioMax Light Film and
developed them using Kodak GBX Developer and Replen-
isher (SantaCruz Biotechnology, Santa Cruz, CA, USA).
Statistical analysis
All the data were presented as mean  standard error of
mean (SEM) unless otherwise indicated. Differences be-
tween groups were analyzed using the Mann-Whitney U test
or the independent t test. All analyses were conducted
using IBM SPSS Statistics for Windows, version 21.0 (IBM
Corp., Armonk, NY, USA). All statistical tests were two-
sided, and p < 0.05 represented statistical significance.
Results
Expression of CD30 on human eosinophils cultured
under different conditions
Indirect immunofluorescence and flow cytometry were used
to examine CD30 expression on eosinophils from 37 healthy
donors. Freshly isolated peripheral blood eosinophils were
found to express low, but consistently detectable, amounts
of CD30. The percentages of eosinophils expressing CD30 in
RPMI 1640 media with 1% FBS, 10% FBS, and IL-5 þ 10% FBS
at 24 hours of culture assessed by flow cytometry were
5.6  1.1%, 3.5  1.7%, and 3.5  1.5%, respectively. The
human eosinophils showed lower CD30 expression when
cultured with 10% FBS compared with 1% FBS at 24 hours.
Addition of IL-5 to eosinophils cultured in RPMI 1640 media
with 10% FBS showed no difference when compared with
eosinophils cultured in RPMI 1640 media with 10% FBS only.
Expression of CD30 on human eosinophils at various
time points
Indirect immunofluorescence and flow cytometry were used
to examine CD30 expression on eosinophils incubated in
RPMI 1640 media supplemented with 10% FBS at various
time points. The percentages of eosinophils expressing
CD30 at 0 hours, 24 hours, 66 hours, and 90 hours of culture
assessed by flow cytometry were 1.3  0.4%, 3.5  1.7%,
148 H.J. Lee et al.8.3  0.7%, and 17.3  0.8%, respectively (p < 0.05). The
CD30 expression on human eosinophils increased in a time-
dependent manner.
Effects of immobilized anti-CD30 mAb on
eosinophil apoptosis
Eosinophils were cultured in 24-well plates with media, IL-5
10 ng/mL, dexamethasone 10mM/mL, Ber-H8 (anti-CD30
mAb) 20 mg/mL, IgG1 20 mg/mL, Ber-H8 20 mg/mL þ IL-5
10 ng/mL, and IgG1 20 mg/mL þ IL-5 10 ng/mL, respectively.
The eosinophil apoptosis rate was determined after 24 hours
and 48 hours. As shown in Figure 1A, eosinophils cultured in
the presence of immobilized anti-CD30 mAb, Ber-H8, resul-
ted in increased apoptosis that was significant at 24 hours of
culture (25.2  5.3%), when compared with eosinophils
cultured with media, IL-5, dexamethasone, IgG1, or IgG1
mAb þ IL-5 (Figure 1A). At 48 hours of culture, culture ofFigure 1. Effects of immobilized anti-CD30 mAb on eosino-
phil apoptosis measured at (A) 24 hours and (B) 48 hours.
*p < 0.05, analyzed using Mann-Whitney U test.
IgG1 Z immunoglobulin G1; IL-5 Z interleukin-5;
mAb Z monoclonal antibodies.eosinophils in the presence of immobilized anti-CD30 mAb,
Ber-H8, resulted in increased apoptosis when compared with
eosinophils cultured with media only and IL-5 (Figure 1B).
Expression of procaspase-8 and caspase-8 assessed
using western blot analysis of human eosinophil
extracts after various stimuli
Eosinophils were cultured in IgG1, IL-5, or anti-CD30 mAb
(Ber-H8)-coated plates and the procaspase-8 and caspase-8
expression was assessed at 24 hours using western blotting
(Figure 2). Pretreatment of eosinophils with IgG1 20 mg/mL,
10 ng/mL of IL-5, or anti-CD30 mAb (Ber-H8) for 24 hours
did not change the procaspase-8 or caspase-8 expression
levels (Figure 2).
Expression of Bcl-2 assessed using western blot
analysis of human eosinophil extracts after various
stimuli
Eosinophils were cultured in IgG1-coated plates, anti-CD30
mAb (Ber-H8)-coated plates þ IL-5, IL-5, or anti-CD30
mAb (Ber-H8)-coated plates and the Bcl-2 expression was
assessed at 24 hours using western blotting (Figure 3).
Pretreatment of eosinophils with 10 ng/mL of IL-5 for 24
hours significantly increased the Bcl-2 expression, whereas
anti-CD30 mAb (Ber-H8) decreased the Bcl-2 expression
(Figure 3).
Expression of procaspase-9 and -3 assessed using
western blot analysis of human eosinophil extracts
after various stimuli
Eosinophils were cultured in IgG1, IL-5, or anti-CD30 mAb
(Ber-H8)-coated plates and the procaspase-9 expression was
assessed at 24 hours using western blotting. Pretreatment of
eosinophils with 10 ng/mL of IL-5 for 24 hours significantly
increased the procaspase-9 expression, whereas anti-CD30
mAb (Ber-H8) significantly decreased the procaspase-9
expression (Figure 4). Pretreatment of eosinophils with
10 ng/mL of IL-5 for 24 hours significantly increased the
procaspase-3 expression, whereas anti-CD30 mAb (Ber-H8)
significantly decreased the procaspase-3 expression
(Figure 5).Figure 2. Western blot analysis of procaspase-8 and caspase-
8 expression in human eosinophil extracts after various stimuli
at 24 hours. IgG1 Z immunoglobulin G1; IL-5 Z interleukin-5;
mAb Z monoclonal antibodies.
Figure 3. Western blot analysis of Bcl-2 expression in human
eosinophil extracts after various stimuli at 24 hours. *p < 0.05,
analyzed using Mann-Whitney U test. IgG1 Z immunoglobulin
G1; IL-5 Z interleukin-5; mAb Z monoclonal antibodies.
Figure 5. Western blot analysis of procaspase-3 expression
in human eosinophil extracts after various stimuli at 24 hours.
*p < 0.05, analyzed using Mann-Whitney U test.
IgG1 Z immunoglobulin G1; IL-5 Z interleukin-5;
mAb Z monoclonal antibodies.
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western blot analysis of human eosinophil extracts
after various stimuli when cultured with caspase-9
and -3 inhibitors
Eosinophils were cultured in IgG1, IL-5, anti-CD30 mAb (Ber-
H8)-coated plates þ caspase-9 (Z-LEHD-FMK, BD Pharmin-
gen) or caspase-3 inhibitors (Z-DEVD-FMK, BD Pharmingen),
or anti-CD30 mAb (Ber-H8)-coated plates and the caspase-9Figure 4. Western blot analysis of procaspase-9 expression
in human eosinophil extracts after various stimuli at 24 hours.
*p < 0.05, analyzed using Mann-Whitney U test.
IgG1 Z immunoglobulin G1; IL-5 Z interleukin-5;
mAb Z monoclonal antibodies.and -3 expressions were assessed at 24 hours using western
blotting. Pretreatment of eosinophils with anti-CD30 mAb
(Ber-H8) significantly increased the caspase-9 expression,
whereas anti-CD30 mAb (Ber-H8) þ caspase-9 inhibitor
decreased the caspase-9 expression (Figure 6). Pretreat-
ment of eosinophils with anti-CD30 mAb (Ber-H8) signifi-
cantly increased the caspase-3 expression, whereas anti-
CD30 mAb (Ber-H8) þ caspase-3 inhibitor decreased the
caspase-3 expression (Figure 7).Figure 6. Western blot analysis of caspase-9 expression in
human eosinophil extracts after treatment of caspase-9 in-
hibitor at 24 hours. *p < 0.05, analyzed using Mann-Whitney U
test. IgG1 Z immunoglobulin G1; mAb Z monoclonal
antibodies.
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immobilized anti-CD30 mAb-induced eosinophil
apoptosis
Eosinophils were cultured with media, anti-CD30 mAb
(Ber-H8)-coated plates, anti-CD30 mAb (Ber-H8)-coated
plates þ caspase-3 inhibitor, anti-CD30 mAb (Ber-H8)-
coated plates þ caspase-9 inhibitor, or IgG1 for 24 hours
and 48 hours, respectively (Figures 8A and 8B). The rate
of annexin V positivity was higher in the eosinophils
cultured in the anti-CD30 mAb (Ber-H8)-coated plates
than in the eosinophils cultured in either media or irrel-
evant control IgG1-coated plates at 24 hours and 48
hours, respectively.
In order to determine the involvement of caspase-9 in
this apoptosis, caspase-9 inhibitors (Z-LEHD-FMK, BD Phar-
mingen) were added to anti-CD30 mAb (Ber-H8)-coated
plates. Addition of 20mM of caspase-9 inhibitors showed a
reduction in anti-CD30 mAb (Ber-H8)-induced eosinophil
apoptosis at 24 hours and 48 hours, respectively (Figures 8A
and 8B). In order to determine the involvement of caspase-
3 in this apoptosis, caspase-3 inhibitors (Z-DEVD-FMK, BD
Pharmingen) were added to anti-CD30 mAb (Ber-H8)-coated
plates. Addition of 20mM of caspase-3 inhibitors showed a
significant reduction in anti-CD30 mAb (Ber-H8)-induced
eosinophil apoptosis at 24 hours and 48 hours, respectively
(Figures 8A and 8B).Figure 7. Western blot analysis of caspase-3 expression in
human eosinophil extracts after treatment of caspase-3 inhibi-
tor at 24 hours. *p < 0.05, analyzed using Mann-Whitney U test.
IgG1 Z immunoglobulin G1; mAb Z monoclonal antibodies.
Figure 8. Effects of caspase-3 and -9 inhibitors on immobi-
lized anti-CD30 mAb-induced eosinophil apoptosis at (A) 24
hours and (B) 48 hours. * p < 0.05, analyzed using Mann-
Whitney U test. IgG1 Z immunoglobulin G1; mAb Z mono-
clonal antibodies.Discussion
In the present in vitro study, we sought to determine
whether Bcl-2 and caspase-9 and -3 are involved in the
signal transduction pathways in human eosinophil apoptosis
through cross-linking of CD30, and found that they are
Bcl-2 and caspases in eosinophil apoptosis by CD30 151critically engaged in the process. To the best of our
knowledge, this is the first study to determine that Bcl-2
and caspase-9 and -3 may play a pivotal role in human
eosinophil apoptosis through cross-linking of CD30.
Our findings that activation of cell surface CD30 by
immobilized anti-CD30 mAb induces intensified apoptosis in
human eosinophils in vitro are in good agreement with
previous studies.3,4,7 This effect was observed only when
the anti-CD30 mAb was immobilized, not in soluble form,
thereby proposing that cross-linking of cell surface mole-
cule CD30 or a second signal may be imperative for the
induction of apoptosis.4
We investigated whether anti-CD30 mAb (clone Ber-H8)
treatment induces human eosinophil apoptosis. As shown in
Figure 1, anti-CD30 mAb (clone Ber-H8) induced strong
human eosinophil apoptosis when compared with the other
stimulators, which correlates well with previous
studies.3,4,7 An important finding worth mentioning in the
present study is that anti-CD30 mAb (clone Ber-H8) induced
stronger human eosinophil apoptosis than dexamethasone,
a well-known potent eosinophil apoptosis inducer.24 This
result suggests that anti-CD30 mAb may well be a promising
drug candidate for regulating human eosinophil survival in
the treatment of allergic diseases in the future.
We determined whether caspase-8 is involved in the
signal transduction pathways in eosinophil apoptosis after
anti-CD30 mAb treatment. Procaspase-8 and caspase-8
expression levels were not changed when stimulated with
IgG1, anti-CD30 mAb, or IL-5, suggesting that caspase-8
pathway is not involved in the anti-CD30 mAb-induced
human eosinophil apoptosis. Previous studies have sug-
gested that several surface molecules such as Fas are
capable of inducing apoptosis in human eosinophils through
cross-linking.6 Fas receptor cross-linking results in death-
inducing signaling complex (DISC) assembly initiating
within minutes of cross-linking, and localizing initially Fas-
associated death domain (FADD) and then caspase-8 to the
receptor complex.25 Although we did not analyze the ac-
tivity of death domain after cross-linking of CD30, it can be
inferred that CD30, unlike Fas, lacks an intracellular death
domain capable of activating the caspase-8 pathway.
We then examined whether Bcl-2 is engaged in the signal
transduction pathways in human eosinophil apoptosis after
anti-CD30 mAb treatment. As shown in Figure 3, Bcl-2
protein was highly expressed when stimulated with IL-5,
an antiapoptotic protein, and its expression was abolished
when stimulated with anti-CD30 mAb, a proapoptotic pro-
tein. The Bcl-2 protein was moderately expressed when
stimulated with both IL-5 and anti-CD30 mAb. A previous
study has reported that when monocytes were stimulated
with a member of the tumor necrosis factor superfamily,
apoptosis was inhibited, the Bcl-2 protein level increased,
and the caspase-3 level decreased compared with unsti-
mulated control cells.26 Another study investigating
whether a T cell survives or dies following T cell receptor
re-engagement found that caspase-mediated cleavage of
antiapoptotic Bcl-2 or Bcl-xL facilitates activation-induced
cell death of T cells, suggesting that cleavage of anti-
apoptotic Bcl-2 and Bcl-xL contributes to the decision be-
tween T cell activation and apoptosis following T cell
receptor (TCR) re-engagement.16 Although we did not
measure expression of other proteins that may be involvedin the mitochondrial pathway, we speculate that the Bcl-2
protein may be engaged in the signal transduction path-
ways in human eosinophil apoptosis after anti-CD30 mAb
treatment.
Next, we explored whether caspase-9 is engaged in the
signal transduction pathways in human eosinophil apoptosis
after anti-CD30 mAb treatment. As shown in Figure 4,
procaspase-9 was highly expressed when stimulated with
IL-5 and its expression was abolished when stimulated with
anti-CD30 mAb. In addition, caspase-9 was highly expressed
when stimulated with anti-CD30 mAb. The caspase-9 pro-
tein was moderately expressed when stimulated with both
anti-CD30 mAb and caspase-9 inhibitor. These findings
imply that upon stimulation by anti-CD30 mAb, procaspase-
9 is converted to caspase-9; thus, it can be inferred that the
caspase-9 pathway is involved in the signal transduction
pathways in human eosinophil apoptosis after anti-CD30
mAb treatment.
We also determined whether caspase-3 is involved in the
signal transduction pathways in human eosinophil apoptosis
after anti-CD30 mAb treatment. As demonstrated in
Figure 5, procaspase-3 was highly expressed when stimu-
lated with IL-5 and its expression was abrogated when
stimulated with anti-CD30 mAb. Furthermore, caspase-3
was highly expressed when stimulated with anti-CD30
mAb. The caspase-3 protein was slightly expressed when
stimulated with both anti-CD30 mAb and caspase-3 inhibi-
tor. These results suggest that when stimulated with anti-
CD30 mAb, procaspase-3 is converted to caspase-3; thus,
we speculate that the caspase-3 pathway is involved in the
signal transduction pathways in human eosinophil apoptosis
after anti-CD30 mAb treatment.
Finally, we determined whether caspase-9 or -3 in-
hibitors decrease human eosinophil apoptotic effects of
anti-CD30 mAb treatment. As shown in Figure 8, caspase-9
and -3 inhibitors significantly decreased human eosinophil
apoptotic effects of anti-CD30 mAb. These data strongly
suggest that caspase-9 and -3 are involved in the signal
transduction pathways for induction of human eosinophil
apoptosis via CD30.
Apoptosis occurs through two main interconnected
pathways which are intrinsic and extrinsic pathways.27 The
intrinsic pathways, also known as mitochondrial pathways,
are triggered by a disparate array of death stress, genomic
stress, metabolic stress, presence of unfolded proteins, and
other stimuli that induce permeabilization of the outer
mitochondrial membrane and release of apoptotic proteins
into the cytosol. Several of these proteins, including Bcl-2,
initiate caspase activation. Progression through the mito-
chondrial pathway induces activation of caspase-9, which
then cleaves procaspase-3, giving activated caspase-3,
which acts as an executioner of eosinophil apoptosis, by
cleaving a multiple of other proteins inside the cells. The
process of apoptosis by various stimuli is commenced by
activating either intrinsic or extrinsic pathways which starts
a series of downstream cascades. From our findings that
anti-CD30 mAb induced eosinophil apoptosis by decreasing
Bcl-2, increasing caspase-9 and -3, and not changing
caspase-8, we speculate that anti-CD30 mAb involves the
intrinsic pathway.
The present study had some limitations. First, we did not
analyze tumor necrosis factor receptor associated factor
152 H.J. Lee et al.(TRAF)-interacting motifs (TIMs) in human eosinophils,
which are activated to recruit TRAF family members, and
activation of multiple signal transduction pathways that are
important in eosinophil apoptosis. Second, we did not
measure various molecules in the Bcl-2 family, which are
known to regulate mitochondrial dysfunction.
In conclusion, we found that Bcl-2 and caspase-9 and -3
are critically involved in anti-CD30 mAb-induced human
eosinophil apoptosis in vitro. Downstream signaling mole-
cules of Bcl-2 and caspase-9 and -3 activations in human
eosinophils remain to be clarified in future studies.
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